Tvardi Therapeutics (TVRD) files 8-K on Phase 2 REVERT IPF update

Tvardi Therapeutics, Inc. (TVRD) filed a Form 8-K announcing a press release about preliminary data from its Phase 2 REVERT trial in idiopathic pulmonary fibrosis.

Accepted by SEC EDGAR 10/14/2025 - 06:11 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. (TVRD) filed a Form 8-K announcing a press release about preliminary data from its Phase 2 REVERT trial in idiopathic pulmonary fibrosis. The company stated the full text of the press release, titled “Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis,” is furnished as Exhibit 99.1 and incorporated by reference.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TVRD disclose in this 8-K filing?

An Item 8.01 Other Events update noting a press release on preliminary Phase 2 REVERT trial data in idiopathic pulmonary fibrosis.

What is the title of the press release referenced by TVRD?

“Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis.”

Where can investors find the full press release for TVRD?

It is furnished as Exhibit 99.1 to the Form 8-K and incorporated by reference.

When was the press release dated?

The press release is dated October 13, 2025.

What exchange does TVRD trade on and under what symbol?

Tvardi Therapeutics trades on The Nasdaq Stock Market LLC under the symbol TVRD.

Does this 8-K include financial statements?

Under Item 9.01, the filing lists Exhibit 99.1 (press release) and Exhibit 104 (cover page Inline XBRL), not financial statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001346830 0001346830 2025-10-13 2025-10-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 13, 2025

TVARDI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36279		75-3175693
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
3 Sugar Creek Ctr. Blvd. Suite 525 Sugar Land, Texas				77478
(Address of principal executive offices)				(Zip Code)

Registrant's telephone number, including area code: (713) 489-8654

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TVRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On October 13, 2025, Tvardi Therapeutics, Inc. issued a press release entitled “Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated October 13, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TVARDI THERAPEUTICS, INC.
Date: October 14, 2025	By:	/s/ Imran Alibhai
	Name:	Imran Alibhai
	Title:	Chief Executive Officer